CN1041087C - 芳基乙酰胺及其制备方法和应用 - Google Patents
芳基乙酰胺及其制备方法和应用 Download PDFInfo
- Publication number
- CN1041087C CN1041087C CN93105673A CN93105673A CN1041087C CN 1041087 C CN1041087 C CN 1041087C CN 93105673 A CN93105673 A CN 93105673A CN 93105673 A CN93105673 A CN 93105673A CN 1041087 C CN1041087 C CN 1041087C
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- hydroxyl pyrrolidine
- ethyl
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4215213A DE4215213A1 (de) | 1992-05-09 | 1992-05-09 | Arylacetamide |
DEP4215213.5 | 1992-05-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1079219A CN1079219A (zh) | 1993-12-08 |
CN1041087C true CN1041087C (zh) | 1998-12-09 |
Family
ID=6458428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93105673A Expired - Lifetime CN1041087C (zh) | 1992-05-09 | 1993-05-08 | 芳基乙酰胺及其制备方法和应用 |
Country Status (22)
Country | Link |
---|---|
US (1) | US5532266A (zh) |
EP (1) | EP0569802B1 (zh) |
JP (1) | JP3210771B2 (zh) |
KR (1) | KR100241637B1 (zh) |
CN (1) | CN1041087C (zh) |
AT (1) | ATE168368T1 (zh) |
AU (1) | AU662051B2 (zh) |
BR (1) | BR1100581A (zh) |
CA (1) | CA2095797C (zh) |
CZ (1) | CZ289961B6 (zh) |
DE (2) | DE4215213A1 (zh) |
DK (1) | DK0569802T3 (zh) |
ES (1) | ES2121030T3 (zh) |
HK (1) | HK1011990A1 (zh) |
HU (1) | HU214578B (zh) |
NO (1) | NO179789C (zh) |
PL (1) | PL173779B1 (zh) |
RU (1) | RU2125041C1 (zh) |
SK (1) | SK282646B6 (zh) |
TW (1) | TW372961B (zh) |
UA (1) | UA32543C2 (zh) |
ZA (1) | ZA933222B (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5137571A (en) * | 1990-06-05 | 1992-08-11 | Rohm And Haas Company | Method for improving thickeners for aqueous systems |
DE4407047A1 (de) * | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
WO1996006078A1 (en) * | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists |
DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US5646151A (en) * | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
WO1997046549A1 (en) * | 1996-06-05 | 1997-12-11 | Novartis Ag | Anti-neurodegeneratively effective xanthene derivatives |
CA2288828A1 (en) * | 1997-07-14 | 1999-01-28 | Adolor Corporation | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith |
DE19827633A1 (de) * | 1998-04-20 | 1999-10-21 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid |
DE10116978A1 (de) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
AU2007207867B2 (en) * | 2001-04-05 | 2009-09-24 | Tioga Pharmaceuticals, Inc. | Kappa-opiate agonists for the treatment of bladder diseases |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
PL371596A1 (en) | 2002-05-17 | 2005-06-27 | Merck Patent Gmbh | Use of compounds that are effective as selective opiate receptor modulators |
DE10259245A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
US6852713B2 (en) * | 2003-04-16 | 2005-02-08 | Adolor Corporation | Lactam derivatives and methods of their use |
US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
EP1680115A1 (en) * | 2003-10-30 | 2006-07-19 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
US7160902B2 (en) * | 2003-11-14 | 2007-01-09 | Adolor Corporation | Amide derivatives and methods of their use |
ATE399164T1 (de) * | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
CA2682608A1 (en) | 2007-03-30 | 2008-10-09 | Tioga Pharmaceuticals, Inc. | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
JP5776554B2 (ja) * | 2009-11-18 | 2015-09-09 | 日本ゼオン株式会社 | フルオレン化合物、当該フルオレン化合物を含有する合成ポリマーの安定化剤、及び当該フルオレン化合物を含有する組成物 |
CN103664727A (zh) * | 2013-12-19 | 2014-03-26 | 无锡万全医药技术有限公司 | 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺 |
CN103772257A (zh) * | 2013-12-31 | 2014-05-07 | 无锡万全医药技术有限公司 | 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法 |
CN109641884B (zh) | 2016-08-18 | 2024-01-02 | 维达克制药有限公司 | 哌嗪衍生物、其药物组合物及其使用方法 |
WO2018119108A1 (en) | 2016-12-21 | 2018-06-28 | Tioga Pharmaceuticals Inc. | Splid pharmaceutical formulations of asimadoline |
WO2019122361A1 (en) | 2017-12-22 | 2019-06-27 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis |
EP3932390A1 (en) | 2020-07-02 | 2022-01-05 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical gel formulation containing asimadoline |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330467A1 (en) * | 1988-02-23 | 1989-08-30 | Glaxo Group Limited | Heterocyclic compounds |
EP0374756A2 (de) * | 1988-12-23 | 1990-06-27 | MERCK PATENT GmbH | Stickstoffhaltige Ringverbindungen |
WO1991008206A1 (en) * | 1989-11-24 | 1991-06-13 | Dr. Lo. Zambeletti S.P.A. | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals |
WO1991008205A1 (en) * | 1989-11-24 | 1991-06-13 | Dr. Lo. Zambeletti S.P.A. | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals |
EP0483580A2 (de) * | 1990-11-02 | 1992-05-06 | MERCK PATENT GmbH | 1-(2-Arylethyl)-Pyrrolidine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192883A (en) * | 1976-04-09 | 1980-03-11 | Pierre Fabre, S.A. | Amides of pyrrolidinoethylamine which can be used in lung therapy |
FR2421891A1 (fr) * | 1977-10-17 | 1979-11-02 | Fabre Sa Pierre | Obtention industrielle d'amides de la pyrrolidine ethyl amine |
GB8601796D0 (en) * | 1986-01-24 | 1986-02-26 | Zambeletti Spa L | Compounds |
DE3916663A1 (de) * | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
-
1992
- 1992-05-09 DE DE4215213A patent/DE4215213A1/de not_active Withdrawn
-
1993
- 1993-04-08 UA UA94010169A patent/UA32543C2/uk unknown
- 1993-05-01 DE DE59308763T patent/DE59308763D1/de not_active Expired - Lifetime
- 1993-05-01 AT AT93107103T patent/ATE168368T1/de active
- 1993-05-01 ES ES93107103T patent/ES2121030T3/es not_active Expired - Lifetime
- 1993-05-01 DK DK93107103T patent/DK0569802T3/da active
- 1993-05-01 EP EP93107103A patent/EP0569802B1/de not_active Expired - Lifetime
- 1993-05-03 AU AU38341/93A patent/AU662051B2/en not_active Expired
- 1993-05-05 CZ CZ1993823A patent/CZ289961B6/cs not_active IP Right Cessation
- 1993-05-06 RU RU93004806/04A patent/RU2125041C1/ru active
- 1993-05-07 ZA ZA933222A patent/ZA933222B/xx unknown
- 1993-05-07 HU HU9301325A patent/HU214578B/hu unknown
- 1993-05-07 NO NO931681A patent/NO179789C/no not_active IP Right Cessation
- 1993-05-07 TW TW082103568A patent/TW372961B/zh not_active IP Right Cessation
- 1993-05-07 CA CA002095797A patent/CA2095797C/en not_active Expired - Lifetime
- 1993-05-07 PL PL93298845A patent/PL173779B1/pl unknown
- 1993-05-08 KR KR1019930007899A patent/KR100241637B1/ko not_active IP Right Cessation
- 1993-05-08 CN CN93105673A patent/CN1041087C/zh not_active Expired - Lifetime
- 1993-05-10 JP JP10844493A patent/JP3210771B2/ja not_active Expired - Lifetime
- 1993-05-12 SK SK468-93A patent/SK282646B6/sk not_active IP Right Cessation
-
1995
- 1995-05-30 US US08/453,811 patent/US5532266A/en not_active Expired - Lifetime
-
1997
- 1997-05-13 BR BR1100581-5A patent/BR1100581A/pt active IP Right Grant
-
1998
- 1998-12-14 HK HK98113248A patent/HK1011990A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330467A1 (en) * | 1988-02-23 | 1989-08-30 | Glaxo Group Limited | Heterocyclic compounds |
EP0374756A2 (de) * | 1988-12-23 | 1990-06-27 | MERCK PATENT GmbH | Stickstoffhaltige Ringverbindungen |
WO1991008206A1 (en) * | 1989-11-24 | 1991-06-13 | Dr. Lo. Zambeletti S.P.A. | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals |
WO1991008205A1 (en) * | 1989-11-24 | 1991-06-13 | Dr. Lo. Zambeletti S.P.A. | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals |
EP0483580A2 (de) * | 1990-11-02 | 1992-05-06 | MERCK PATENT GmbH | 1-(2-Arylethyl)-Pyrrolidine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1041087C (zh) | 芳基乙酰胺及其制备方法和应用 | |
CN1109022C (zh) | 芳基链烷酰基哒嗪衍生物、其制备方法和含有它们的药物以及应用 | |
CN1036456C (zh) | 氨基取代的吡唑 | |
CN1187330C (zh) | 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用 | |
CN1106811A (zh) | 哌啶和哌嗪衍生物 | |
CN1168720C (zh) | 芳基链烷酰基哒嗪化合物 | |
CN1047385C (zh) | 3-吲哚基哌啶和含有它们的药物组合物 | |
CN1031842A (zh) | 新二唑 | |
CN1244578C (zh) | 取代的苯并呋喃-2-甲酰胺衍生物 | |
CN1127254A (zh) | 新的1,3-二氢-2H-吡咯并[2,3-b]吡啶-2-酮和噁唑并[4,5-b]吡啶-2(3H)-酮化合物,它们的制备方法以及含有它们的药物组合物 | |
CN1030986C (zh) | 制备吡咯并吡嗪的方法 | |
CN1309654A (zh) | 联苯基衍生物 | |
CN1798744A (zh) | 作为nmda/nr2b拮抗剂的3-氟-哌啶化合物 | |
CN1055690C (zh) | 4-芳氧基和4-芳硫基哌啶衍生物,其制备方法,含它们的药物组合物及其用途 | |
CN1058207A (zh) | 新的哌啶化合物及其制备方法 | |
CN1069640C (zh) | 噁唑烷酮衍生物,其制备方法及含它们的药物组合物 | |
CN1145617A (zh) | 吲哚衍生物及含它们的药物 | |
CN1155570C (zh) | 新的氰基-吲哚5-羟色胺再摄取抑制剂化合物、其制备方法和含有它们的药物组合物 | |
CN1665508A (zh) | 吡唑并[4,3-d]嘧啶类化合物的应用 | |
CN1111620A (zh) | 新的烷氨基茚满化合物,其制备方法,含这类化合物的药物组合物 | |
CN1063438C (zh) | 链烯基-苯甲酰胍衍生物及其制备和用途 | |
CN1538845A (zh) | 作为Xa因子抑制剂的苯基衍生物 | |
CN1741996A (zh) | 酰胺衍生物及其作为因子xa抑制剂的用途 | |
CN1871013A (zh) | 作为mao-b抑制剂的苯并氮杂䓬衍生物 | |
CN1146545C (zh) | 苯甲酰基哒嗪 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DIOGA PHARMACEUTICAL COMPANY Free format text: FORMER OWNER: MERCK PATENT GMBH Effective date: 20070720 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070720 Address after: American California Patentee after: Merck Patent GmbH Address before: Darmstadt, Federal Republic of Germany Patentee before: Merck Patent GmbH |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20130508 Granted publication date: 19981209 |